Nasus Pharma's Intranasal Ondansetron Shows Promising Preclinical Results
Event summary
- Nasus Pharma's NS003 intranasal ondansetron demonstrated comparable pharmacokinetic profile to intravenous ondansetron in preclinical animal study.
- NS003 showed a favorable safety profile at four times the test dose with no adverse effects observed.
- First-in-human pharmacokinetic study for NS003 planned for Q3 2026.
- Ondansetron market size exceeded $1.5 billion in peak sales, with over 12 million prescriptions in 2023.
The big picture
Nasus Pharma's positive preclinical results for NS003 highlight the potential of intranasal drug delivery in addressing unmet needs in nausea and vomiting management. The company's proprietary powder-based intranasal technology aims to provide a convenient, fast-onset alternative to intravenous treatments, aligning with broader industry trends toward needle-free, patient-friendly drug administration. The success of NS003 could position Nasus Pharma as a key player in the intranasal pharmaceutical market, with significant implications for both chemotherapy and post-operative care.
What we're watching
- Clinical Progression
- How the first-in-human study in Q3 2026 will validate NS003's pharmacokinetic and safety profile in humans.
- Market Penetration
- Whether NS003 can capture a significant share of the $1.5 billion ondansetron market by addressing unmet needs in chemotherapy and post-operative nausea.
- Pipeline Expansion
- The pace at which Nasus Pharma advances its other pipeline products, particularly NS002 for anaphylaxis, following the NS003 study.
Related topics